CClinicalTrials.gg
Status unknownNCT02662699Updated May 19, 2017

Clinical Signs and Symptoms of Anemia in Patients Over 75 Years

An observational study in Anemia, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2017-05-19.

Sponsored by University Hospital, Strasbourg, France · Observational

The sponsor has not verified this record recently (last verified May 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
40
Ages
75 Years and older
Sex
All
01

Study summary

Anemia is a common pathology in geriatrics. According to the World Health Organization it affects 23.9% of subjects over 60 years in the world, and 8% of patients over 60 years in Europe. A prevalence that increases with the age and twice in individuals over 85 years.

02

Conditions studied

  • Anemia

Browse trials for

Keywords

  • Anemia
  • Hematologic Diseases
  • Erythrocytes
  • Hemoglobin
  • Hemolytic
03

In context

Anemia

1,733 studies on the registry are indexed under Anemia; 246 are open to participants now.

This study's planned enrollment of 40 is below the median of 200 across 326 observational studies indexed under Anemia.

Browse Anemia studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Anemic patients

Inclusion criteria

  • Adult over 75 years old, male or female

Exclusion criteria

Exclusion criteria:

  • Transfusion within 3 months, acute anemia / deglobulisation
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
40 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Laboratory tests

    Time frame: 1 hour after hospitalization

07

Study locations

1 of 1 sites recruiting
  • Service de Médecine Interne, diabète et maladies métaboliques - Médicale B
    Strasbourg, 67091, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02662699
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Jan 25, 2016
Start date
Oct 2016
Primary completion
Jan 2018 (estimated)
Completion
Jan 2018 (estimated)
Last update
May 19, 2017

Study contacts

Emmanuel ANDRES, MD, PhD
Contact
Emmanuel.ANDRES@chru-strasbourg.fr
33 3 88 11 50 66
Mohamed Hassanine BEN MALEK, MD
Contact
hassaninebenmalek@hotmail.fr
33 3 6 75 44 30 79
Emmanuel ANDRES
study director · University Hospital, Strasbourg, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion